v3.26.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration risks (Details)
3 Months Ended 6 Months Ended
Aug. 01, 2026
Feb. 20, 2026
Sep. 13, 2024
Jun. 30, 2026
USD ($)
customer
Jun. 30, 2025
USD ($)
customer
Jun. 30, 2026
USD ($)
customer
Jun. 30, 2025
USD ($)
customer
Concentration risks              
Aggregate dollar amount of net sales       $ 7,200,623 $ 10,445,733 $ 14,378,020 $ 18,740,906
Syringes and needles              
Concentration risks              
Tariff, percentage 112.50%   100.00%        
Ad valorem duty, percentage   10.00%          
Other products              
Concentration risks              
Aggregate dollar amount of net sales       $ 7,713 $ 19,131 $ 14,702 $ 26,815
Tariff, percentage     12.50%        
Net Sales | Customer Concentration Risk              
Concentration risks              
Number of significant customers | customer       2 3 2 3
Net Sales | Customer Concentration Risk | Significant customers              
Concentration risks              
Aggregate dollar amount of net sales       $ 3,500,000 $ 6,000,000 $ 6,900,000 $ 10,300,000
Concentration risk, percentage       49.10% 57.20% 48.10% 55.00%
Cost of Sales, Manufacturing | Supplier Concentration Risk | China              
Concentration risks              
Concentration risk, percentage       53.50% 62.00% 57.60% 62.00%